| Literature DB >> 28920717 |
Krisztián Nagyiványi1, Lajos Géczi1.
Abstract
Until the past decade, therapeutic options for unresectable and/or metastatic renal cell carcinoma were limited. Renal cell carcinoma is generally resistant to conventional chemotherapy, and only a small percentage of patients with renal cell carcinoma benefit from cytokine treatment. Since 2005, the advances in target-based therapy and immunotherapy modalities have created a paradigm shift in the treatment of renal cell carcinoma. Herein, we review the most up-to-date practices and emerging therapies for the treatment of renal cell carcinoma and focus on the threrapy caused side-effects and side-effect management. Orv Hetil. 2017; 158(38): 1488-1502.Entities:
Keywords: biomarkerek; biomarkers; célzott (targeted) kezelések; immunotherapy; immunterápia; mTOR-gátlók; mammalian target of rapamycin inhibitors; mellékhatások; renal cell carcinoma; side-effects; targeted treatments; tirozinkináz-gátlók; tyrosine kinase inhibitors; vascular endothelial growth factor inhibitors; vascularis endothelialis növekedési faktort gátlók; vesesejtes carcinoma
Mesh：
Substances：
Year: 2017 PMID： 28920717 DOI： 10.1556/650.2017.30819
Source DB: PubMed Journal: Orv Hetil ISSN： 0030-6002 Impact factor: 0.540